[1] Mundt N, Kenzler L, Spehr M. Purinergic signaling in spermatogenesis[J]. Front Endocrinol (Lausanne), 2022, 13(4): 867011.
[2] Rossato M, Favaretto F, Granzotto M, et al. Molecular and pharmacological evidence for the expression of multiple functional P2 purinergic receptors in human adipocytes[J]. Molecules, 2022, 27(6): 1913.
[3] Spek A, Li B, Rutz B, et al. Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists[J]. Naunyn Schmiedebergs Arch Pharmacol, 2021, 394(6): 1113-1131.
[4] Luz H L, Reichel M, Unwin R J, et al. P2X7 receptor stimulation is not required for oxalate crystal-induced kidney injury[J]. 2019, 9(1): 20086.
[5] Granata S, Masola V, Zoratti E, et al. NLRP3 inflammasome activation in dialyzed chronic kidney disease patients[J]. PLoS One, 2015, 10(3): e0122272.
[6] Yan Y, Bai J, Zhou X, et al. P2X7 receptor inhibition protects against ischemic acute kidney injury in mice[J]. Am J Physiol Cell Physiol, 2015, 308(6): 463-472.
[7] Pereira J M S, Barreira A L, Gomes C R, et al. Brilliant blue G, a P2X7 receptor antagonist, attenuates early phase of renal inflammation, interstitial fibrosis and is associated with renal cell proliferation in ureteral obstruction in rats[J]. BMC Nephrol, 2020, 21(1): 206.
[8] Potthoff S A, Stegbauer J, Becker J, et al. P2Y2 receptor deficiency aggravates chronic kidney disease progression[J]. Front Physiol, 2013, 4(9): 234.
[9] Han S J, Lovaszi M, Kim M, et al. P2X4 receptor exacerbates ischemic AKI and induces renal proximal tubular NLRP3 inflammasome signaling[J]. FASEB J, 2020, 34(4): 5465-5482.
[10] Jain N, Phadnis M A, Hunt S L, et al. Comparative effectiveness and safety of oral p2y12 inhibitors in patients on chronic dialysis[J]. Kidney Int Rep, 2021, 6(9): 2381-2391.
[11] Farmakis I T, Doundoulakis I, Zafeiropoulos S, et al. Comparative efficacy and safety of oral P2Y(12) inhibitors for patients with chronic kidney disease and acute coronary syndrome: a network meta-analysis[J]. Hellenic J Cardiol, 2022, 63(2): 40-65.
[12] Arkhipov S N, Pavlov T S. ATP release into ADPKD cysts via pannexin-1/P2X7 channels decreases ENaC activity[J]. Biochem Biophys Res Commun, 2019, 513(1): 166-171.
[13] Vallon V, Unwin R, Inscho E W, et al. Extracellular nucleotides and P2 receptors in renal function[J]. Physiol Rev, 2020, 100(1): 211-269.
[14] Arkhipov S N, Potter D L, Geurts A M, et al. Knockout of P2rx7 purinergic receptor attenuates cyst growth in a rat model of ARPKD[J]. Am J Physiol Renal Physiol, 2019, 317(6): 1649-1655.
[15] Gong D, Zhang J, Chen Y, et al. The m(6)A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca(2+) influx modulating ERK1/2 phosphorylation and MMP9 signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 233.
[16] Liu Z, Liu Y, Xu L, et al. P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma[J]. Cancer Sci, 2015, 106(9): 1224-1231.
[17] Monaghan M T, Bailey M A, Unwin R J. Purinergic signalling in the kidney: in physiology and disease[J]. Biochem Pharmacol, 2021, 187(5): 114389.
[18] Tempest H V, Dixon A K, Turner W H, et al. P2X and P2X receptor expression in human bladder urothelium and changes in interstitial cystitis[J]. BJU Int, 2004, 93(9): 1344-1348.
[19] Burnstock G. Purinergic signalling in the urinary tract in health and disease[J]. Purinergic Signal, 2014, 10(1): 103-155.
[20] Wu K C, Chiang B J, Tsai W H, et al. I-Tiao-Gung extract through its active component daidzin improves cyclophosphamide-induced bladder dysfunction in rat model[J]. Neurourol Urodyn, 2018, 37(8): 2560-2570.
[21] Santander J, Plata M, Zuluaga L, et al. What is the real burden of the overactive bladder? Results from a national prevalence study[J]. Neurourol Urodyn, 2022, 41(4): 926-934.
[22] Firouzmand S, Ajori L, Towse J, et al. Investigating the associations of mucosal P2Y6 receptor expression and urinary ATP and ADP concentrations, with symptoms of overactive bladder[J]. Neurourol Urodyn, 2020, 39(3): 926-934.
[23] Kira S, Yoshiyama M. P2Y6-deficiency increases micturition frequency and attenuates sustained contractility of the urinary bladder in mice[J]. Sci Rep, 2017, 7(1): 771.
[24] Lee W C, Wu C C, Chuang Y C, et al. Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate cyclophosphamide-induced ongoing bladder overactivity and acidic adenosine triphosphate solution-induced hyperactivity on rats prestimulated bladder[J]. J Ethnopharmacol, 2016, 184(5): 1-9.
[25] Wang L, Fu Y B, Liu Y, et al. Moxibustion attenuates neurogenic detrusor overactivity in spinal cord injury rats by inhibiting M2/ATP/P2X3 pathway[J]. Brain Res, 2022, 1788(8): 147926.
[26] Sterle I, Zupancic D, Romih R. Correlation between urothelial differentiation and sensory proteins P2X3, P2X5, TRPV1, and TRPV4 in normal urothelium and papillary carcinoma of human bladder[J]. Biomed Res Int, 2014, 2014(8): 805236.
[27] Dietrich F, Cappellari A R, Filippi-Chiela E C, et al. High P2X6 receptor expression in human bladder cancer predicts good survival prognosis[J]. Mol Cell Biochem, 2022, 477(8): 2047-2057.
[28] Ding M, Zhan H, Liao X, et al. Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer[J]. Int J Biol Sci, 2018, 14(10): 1268-1276.
[29] Zhang H, Liu L, Yang Z, et al. P2X7 receptor mediates activation of microglial cells in prostate of chemically irritated rats[J]. Int Braz J Urol, 2013, 39(2): 276-285.
[30] Ziganshin A U, Ivanova D V, Zubkov E A, et al. Involvement of P2 receptors in the contractile activity of the bladder in patients with benign prostatic hyperplasia[J]. Urologiia, 2021, 11(5): 10-14.
[31] Silva-Ramos M, Silva I, Faria M, et al. Activation of prejunctional P2x2/3 heterotrimers by ATP enhances the cholinergic tone in obstructed human urinary bladders[J]. J Pharmacol Exp Ther, 2020, 372(1): 63-72.
[32] Khalafalla M G, Tran H N, Khalafalla F G. P2Y purinergic signaling in prostate cancer: emerging insights into pathophysiology and therapy[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(3): 188732.
[33] Maynard J P, Lu J, Vidal I, et al. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer[J]. 2022, 256(2): 149-163.
[34] He J, Zhou Y. Inhibiting the P2X4 receptor suppresses prostate cancer growth in vitro and in vivo, suggesting a potential clinical target[J]. J Pathol, 2020, 9(11): 2511.
[35] Reyna-Jeldes M, Díaz-Mu?oz M. Autocrine and paracrine purinergic signaling in the most lethal types of cancer[J]. Purinergic Signal, 2021, 17(3): 345-370.
[36] Ghalali A, Wiklund F, Zheng H, et al. Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells[J]. Carcinogenesis, 2014, 35(7): 1547-1555.
[37] Le H T T, Rimpilainen T, Konda M S. Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent[J]. Sci Rep, 2019, 9(1): 18938.
[38] Le H T T, Murugesan A, Candeias N R, et al. P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer[J]. Apoptosis, 2022, 27(4): 283-295.
[39] Le H T T, Murugesan A, Ramesh T, et al. Molecular interaction of HIC, an agonist of P2Y1 receptor, and its role in prostate cancer apoptosis[J]. Int J Biol Macromol, 2021, 189(10): 142-150.
[40] Yan Y, Liang Y, Ding T, et al. PI3K/Akt signaling pathway may be involved in MCP-1-induced P2X4R expression in cultured microglia and cancer-induced bone pain rats[J]. Neurosci Lett, 2019, 701(5): 100-105.